bempedoic acid/ezetimibe (Nexlizet)
Jump to navigation
Jump to search
Indications
- for use in combination with statin for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease
Dosage
- 180 mg bempedoic acid + 10 mg ezetimibe daily
- with or without food, swallow capsule whole
Adverse effects
- muscle spasms, back pain, arthralgia
- abdominal pain or discomfort, pain in extremity
- bronchitis, upper respiratory tract infection, sinusitis
- hyperuricemia, anemia, elevated serum transaminases, diarrhea, fatigue
- slight increase in tendon rupture[3]
- benign prostatic hyperplasia[3]
- atrial fibrillation[3]
Mechanism of action
- bempedoic acid is a ATP-citrate lyase inhibitor that lowers LDL-cholesterol by suppressing cholesterol synthesis & upregulating LDL receptors
- ezetimibe inhibits cholesterol absorption in the gut
References
- ↑ Stiles S FDA Approves Bempedoic Acid-Ezetimibe Combination for ASCVD, Heterozygous FH Medscape - Feb 26, 2020. https://www.medscape.com/viewarticle/925808
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION NEXLIZET (bempedoic acid & ezetimibe) tablets, for oral use https://pi.esperion.com/nexlizet/nexlizet-pi.pdf
- ↑ 3.0 3.1 3.2 3.3 Lloyd-Jones DM, Morris PB, Ballantyne CM et al 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct, 80 (14) 1366-1418 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36031461 https://www.jacc.org/doi/10.1016/j.jacc.2022.07.006
- ↑ Ballantyne CM, Banach M, Mancini GBJ et al Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195-203. Epub 2018 Jun 12. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29910030 Free Article